Elicio Therapeutics (ELTX) Capital Leases (2021 - 2022)
Elicio Therapeutics' (ELTX) quarterly Capital Leases came in at $168000.0 in Q4 2022, down 28.51% on a YoY basis from $235000.0 in Q4 2021, and down 9.68% quarter-over-quarter from $186000.0 in Q3 2022.
Powered by 
Analysis
Elicio Therapeutics (ELTX) Capital Leases (2021 - 2022) Analysis & Trends
Elicio Therapeutics (ELTX) has reported Capital Leases for 2 consecutive years, with $168000.0 the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Capital Leases fell 28.51% year-over-year to $168000.0; the trailing twelve-month figure through Dec 2022 stood at $168000.0 (down 28.51% YoY), and the FY2022 full-year result was $168000.0, down 28.51% from the prior year.
- Capital Leases fell to $168000.0 in Q4 2022 per ELTX's latest filing, from $186000.0 in the prior quarter.
- Across five years, Capital Leases topped out at $235000.0 in Q4 2021 and bottomed at $168000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Elicio Therapeutics | 40.60 Mn | 17.10 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 168,000.00 |
| Sep 30, 2022 | 186,000.00 |
| Jun 30, 2022 | 202,000.00 |
| Mar 31, 2022 | 219,000.00 |
| Dec 31, 2021 | 235,000.00 |